Immunogenicity of RSVPreF3 Vaccine in Immunocompromised Persons — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Immunogenicity of RSVPreF3 Vaccine in Immunocompromised Persons — Stella

Recruiting

Back to Respiratory Syncytial Virus (RSV) trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

United States

Johns Hopkins University, Baltimore, Maryland

Key details

Phase

Safety & dosing

Sponsor

Johns Hopkins University

Collaborators

GlaxoSmithKline

Enrollment target

~170 participants

Started

December 2025

Primary completion

November 2026

Age range

18 Years and older

Last updated December 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov